The oncotropic and oncolytic behaviors of certain autonomous rodent parvoviruses make them promising vectors for anticancer gene therapies. However, these parvoviruses are often not potent enough to kill all tumor cells equally well. With the aim of enhancing the intrinsic antitumor effect and the range of natural parvoviruses, a recombinant H1 parvovirus vector was constructed that produces the Apoptin protein, a tumor cell -specific, p53 -independent, Bcl -2 -insensitive apoptotic effector. We compared the apoptotic activity exerted by a recombinant hH1 / Apoptin virus with that of a Green Fluorescent Protein ( GFP ) -transducing recombinant virus, hH1 / GFP, in three human tumor cell lines differing in their susceptibility to wild -type parvovirus H1 -induced killing. We found that in cells that were rather resistant to the basal cytotoxic effect of wild -type H1 or the GFP recombinant virus, a parvovirus that expressed Apoptin caused a pronounced, additional cytotoxic effect. In contrast to its enhanced cytotoxicity toward tumor cells, hH1 / Apoptin virus was not more toxic to normal human fibroblasts than was the wild -type H1 virus. Taken together, these data indicate that enhancing the oncotropic behavior of wild -type H1 parvoviruses with the tumor -specific apoptotic potency of Apoptin should lead to an effective replicative parvoviral vector. Cancer Gene Therapy ( 2001 ) 8, 958 -965 
C ertain autonomous rodent parvoviruses have been shown to replicate preferentially in, and consequently kill transformed cells in vitro compared with their corresponding nontransformed parental cells. 1, 2 This feature makes such parvoviruses attractive tools for tumor-targeted gene therapy. 2, 3 The viral nonstructural protein 1 (NS1 ) is important for parvoviral replication and is a major determinant of parvovirus -induced cell death. Rodent parvoviruses can inhibit the growth of spontaneous, chemically and virally induced tumors and can ablate the growth of implanted human tumors in laboratory animals ( reviewed in Ref. 1 ). The oncotropic and lytic activities exerted by autonomous parvoviruses in vitro are likely to contribute, at least in part, to the oncosuppressive capacity of these viruses in animals.
Despite the oncoreductive properties of parvoviruses, tumors may still arise in infected animals, indicating that natural parvoviruses are not always potent enough to suppress tumor formation. One explanation may be that different tumor cell types differ in their susceptibility to infection. Alternatively, it is possible that not all tumor cell types are equally sensitive to the cytotoxic effect of the NS1 protein; this theory is supported by in vitro variability in different tumor cell lines. Indeed, the parvovirus H1 strain induces morphological changes that are characteristic for apoptosis in human monocytic cells, 4 and inhibition assays suggest that parvovirus H1 induces a caspase 3-dependent apoptosis pathway in rat glioblastoma and human hepatoma cells. 5, 6 Providing the virus with a more potent cytotoxic protein may hopefully improve its sometimes low antitumor potency, which hinders the use of natural parvoviruses as anticancer agents.
It was shown previously that it is possible to generate recombinant parvoviruses that retain the oncotropic behavior of the wild -type virus in cell cultures, 7 and can thus serve as appropriate models for tumor-targeted transgene expression in animals. Replication -defective recombinant viruses have been described in which the expression of immunemodulatory transgenes was placed under the control of the NS1 -transactivated P38 promoter in place of the capsid genes. 7, 8 These recombinant parvoviruses still express the viral NS -encoding genes under their native promoter, which results in a strong transactivation of the P38 promoter and the amplification of viral DNA in permissive tumor cells. However, their original oncolytic potential is not improved. Insertion of a suitable cytotoxic transgene with the proper antitumor specificity and potency into such a parvovirus could thus greatly enhance its cytotoxicity toward a range of tumor types, and thus its therapeutic potential.
Apoptin, the product of the chicken anemia virus VP3 gene, has been shown to selectively and efficiently kill a very wide range of tumor-derived human cells while sparing nontransformed primary cells. 9 Apoptin induces apoptosis in human tumor cells irrespective of their p53 status 10 or other antiapoptotic genetic lesions. For instance, Bcl -2 or BAG -1 overexpression does not protect cells from Apoptin -induced apoptosis 11 -13 and several inhibitors of upstream caspases ( e.g., CrmA ) or the p53 pathway (Ad5 E1B -55k ) failed to affect Apoptin -induced cell death.
14 Thus, tumors containing lesions in any of these antiapoptotic genes or pathways should still be susceptible to Apoptin, in contrast to therapies that rely on an intact cellular apoptotic machinery, such as chemotherapy. Because of its small size (363 nucleotides ), the Apoptin -encoding VP3 gene can be inserted into vectors with low insertional capacities such as those derived from parvoviruses, adenoassociated viruses, and papovaviruses. A transgenic adenovirus expressing Apoptin has been shown to have a significant antitumor effect in vivo, 15 while showing no adverse toxic effects. However, adenovirus transgene delivery to tumors has several serious well-known drawbacks, such as low efficiency of transduction in vivo, low intratumoral spreading, immunogenicity or preexisting immunity, clearance from the bloodstream, and a lack of tumor specificity. A replicative oncotropic virus would in principle be a much more efficient way to deliver an antitumor agent such as Apoptin.
We conducted the present study to determine whether Apoptin would potentiate tumor-cell killing mediated by a nonreplicating parvoviral vector, under conditions in which the parvoviral NS proteins alone are inefficient in the removal of these cells. Our data show that Apoptin has no negative effect on the replication of H1 vectors and that it broadens the spectrum of human tumor cells that can be killed by such a recombinant H1 parvovirus. These features open the way for research into the applicability of a replicative Apoptin -expressing parvovirus.
METHODS

Cell lines and recombinant parvoviruses
Human cells were grown in DMEM (293T, HeLa, Saos-2, U2OS, VH10 ) supplemented with 10% FCS, glutamine, and antibiotics ( all additives from Life Technologies, Eggenstein, Germany ). NB -E cells were grown in MEM supplemented with 5% FCS and additives (see above ). The nonestablished normal diploid human fibroblast strain VH10 was used between its 12th and 16th passage.
The NdeI ( blunt )/ BamHI fragment from pET-16b -13.6, containing the full -length chicken anemia virus VP3 gene ( M. H. M. Noteborn, unpublished data ) was inserted into the MluI ( blunt )/ BamHI site of the parvovirus H1 DNA clone phH1Á400, 8 generating the recombinant DNA clone phH1 / Apoptin. As depicted in Figure 1 , phH1 /Apoptin contains the VP3 gene under control of the parvovirus H1 P38 promoter. The recombinant parvoviral DNA clone phH1 / GFP, in which the P38 promoter governs expression of the GFP gene, was constructed in a similar way. 16 The hH1 / GFP virus was used as a control vector in all experiments. The recombinant DNA clones were propagated in the recBC sbcB recF Escherichia coli strain SURE (Stratagene, Heidelberg, Germany ) to minimize the possible occurrence of recombinations or deletions. The packaging helper construct pBK -CMVVP contains the parvovirus H1 gene encoding the viral capsid proteins VP1 and VP2 under the control of the human cytomegalovirus immediate -early promoter. 8 It was amplified in pXL1 -Blue MRF 0 bacteria ( Stratagene ). Plasmid DNAs were purified using Qiagen Maxi -kit columns ( Qiagen, Hilden, Germany ).
Production and titration of virus stocks
293T cells ( 2Â10 6 cells per 10 -cm Petri plate) were transfected with 6 g recombinant DNA clone and 12 g helper plasmid using the standard calcium phosphate coprecipitation technique. 17 Three days after transfection, the medium was removed and the cells were washed with PBS. After three freeze /thaw cycles in 50 mM Tris -HCl ( pH 8.7) -0.5 mM EDTA, cell debris were scraped from the plates, centrifuged, and the supernatant was recovered. The pellet was subjected to two additional freeze /thaw cycles followed by centrifugation. The clarified virus suspensions were pooled and the virus was purified by cesium chloride centrifugation. 18 Titers of recombinant and natural virus were determined by infected cell hybridization and plaque assays on NB -E indicator cells, and expressed as replication units (RU ) and plaque -forming units (pfu ) per milliliter virus suspension, respectively. 8 The titers of wild -type H1 virus stocks determined by plaque assays or by infected cell 
Virus infection, indirect immunofluorescence microscopy, and determination of H1 virus -induced apoptotic cell death
For microscopic analyses, monolayer cultures of 10 4 HeLa, VH10, Saos-2, or U2OS cells were seeded on coverslips in 6 -cm dishes, incubated for 24 hours, and infected with recombinant virus for 1 hour at 378C at multiplicities of infection (MOIs ) of 3 (HeLa, Saos -2, U2OS ) or 10 (VH10 ) RU /cell of recombinant virus. To determine the intracellular localization of both Apoptin and NS1 in the same cells, cultures were harvested at several time points after virus infection, and fixed in 80% acetone for 10 minutes at room temperature. The expression of both GFP and NS1 at the single -cell level was determined in cells first fixed in 1% formaldehyde for 10 minutes, then rinsed for 5 minutes in ice -cold methanol ( 100% ) followed by a 2 minutes rinse in ice -cold acetone (100% ). Indirect immunofluorescence 19 was performed with a 5 -fold dilution of the mouse mAb 111.3 directed against Apoptin, 9 and a 1000 -fold dilution of the NS1 -specific rabbit antiserum SP8. 20 Fluorescein isothiocyanate -labeled goat anti -mouse antibodies and rhodamine -conjugated goat anti -rabbit antibodies ( Jackson Immunoresearch Laboratories, West Grove, PA ) were used for secondary immunostaining of Apoptin and NS1, respectively. In parallel, nuclear DNA was stained with 1 g /mL DAPI in 0.1 M Tris -HCl (pH 8.0 ) containing 90% glycerol and 2% 1,4 diazabicyclo[ 2,2,2 ]-octane.
Cell death was expressed as the fraction of NS1 and GFP -positive cells (infection with hH1 / GFP vector ), or NS1 and Apoptin -positive cells ( infection with hH1 / Apoptin virus ) showing abnormal nuclear staining with DAPI (4,6 -diamidino -2 -phenylindole ), versus the total number of positive cells. 9, 10 Three independent experiments were carried out in which at least 100 cells positive for NS1 and GFP or NS1 and Apoptin were examined for each time point. The susceptibilities of the various cells to killing by wild -type H1 virus infection ( MOIs of 3, 5, and 10 pfu / cell ) was determined by colony -forming assays. 21 Receptor-destroying enzyme (BioWhittaker, Verviers, Belgium ) was added to the cultures to prevent secondary parvovirus infections.
Immunoblot analysis
Cultures of 3Â10 5 cells were infected with recombinant virus at an MOI of 3 RU /cell. Cells were collected by centrifugation after removal from the culture plates, counted, and suspended in buffer containing protease inhibitors (10 M Pepstatin A, 1 mM EDTA, 10 mM Na 2 SO 3 , 1 mM phenylmethylsulfonyl fluoride in PBS ). Lysis buffer was added to the cell suspension to a final concentration of wn>293.75 mM Tris -HCl pH 6.8, 9 M urea, 15% glycerol, 3% ( vol /vol ) sodium dodecyl sulfate (SDS ), 0.0045% bromophenol blue, and 7.5% -mercaptoethanol. Protein aliquots from 10 5 cells were separated by 12% SDSpolyacrylamide gel electrophoresis and transferred onto Hybond-H + membranes ( Amersham Pharmacia Biotech, Freiburg, Germany ). Equal loading of proteins was confirmed by Ponceau-S staining. Immunodetection of antigens was performed with specific antibodies: mouse mAb 111.3 ( 1:5 ) for Apoptin, rabbit SP8 serum (1:1000 ) for NS1 and rabbit anti -GFP serum (1:1000 ) (a kind gift of M. Müller, Heidelberg). The protein complexes were detected by autoradiography using appropriate peroxidase -conjugated secondary antibodies and the enhanced chemiluminescence detection reagent ECL + (Amersham Pharmacia Biotech ).
FACS analysis
Cells were infected with hH1 /GFP at an MOI of 3 RU /cell, incubated for 42 hours, trypsinized, and washed twice with cold PBS supplemented with 1% (vol /vol ) pasteurized protein solution (PPS, 0.8 g /L; CLB, Amsterdam, the Netherlands ). After centrifugation the pellets were resuspended in 0.5 mL cold PBS / PPS, and the GFP fluorescence was analyzed using a FACScan apparatus (Becton Dickinson, Heidelberg, Germany ).
RESULTS
Construction of recombinant parvoviruses and expression of the respective transgenes
To examine the possible benefit of a parvovirus vector delivering Apoptin, we constructed the recombinant H1 virus -based DNA clone phH1 /Apoptin, which contains the parvoviral NS genes and the native viral P38 promoter controlling a transgene encoding Apoptin. As a control vector, an identical construct (phH1 / GFP ) was used, which contains the gene for GFP, encoding a marker protein, instead of the Apoptin gene ( Fig 1) . Cotransfection of 293T cells with phH1 /GFP or phH1 /Apoptin and the helper construct pBK -CMVVP resulted in the production of recombinant hH1 /GFP and hH1 /Apoptin virus vectors, respectively. The virus titers that were obtained ranged between 1 and 5Â10 7 RU / mL, consistent with those achieved with other recombinant H1 virusderived vectors. 16, 22 The recombinant virus stocks were contaminated with a maximum of 0.08% replicationcompetent virus.
Because the P38 promoter can be strongly transactivated by NS1, GFP and Apoptin should be produced in parvovirus -susceptible cells upon infection with recombinant viruses. HeLa cells were infected with hH1 /GFP or hH1 /Apoptin vectors at an MOI of 3 RU /cell, and whole cell lysates were analyzed by immunoblotting for the expression of NS1 and the respective transgene products Apoptin and GFP. Both GFP ( Fig 2B ) and Apoptin (Fig 2C ) could be detected readily, indicating that the transgenes were transcribed efficiently in these constructs. Moreover, the expression of the transgenic proteins did not negatively influence NS1 expression. Typically, two NS1 species were detected, which were previously assigned to phosphorylated ( marked with an arrow in Fig 2A ) and underphosphorylated forms of NS1. These data indicate that the recombinant parvoviruses were not diminished in the amount of NS1 they made, and could be further tested for a broadening of the spectrum of susceptible cells.
Susceptibility of different tumor cells to parvoviral cytotoxicity
We examined a number of tumor cell lines for their resistance to wild -type parvovirus -mediated cell killing to select a panel of tumor cell lines differentially susceptible to wildtype H1 parvovirus. Cells were infected at several MOIs with wild -type H1 parvovirus, and cell survival was measured by clonogenicity. To avoid the effect of secondary virus infections, receptor-destroying enzyme was added to the cultures. The panel of three tumor cell lines with high, medium, and low susceptibility to H1 parvovirus is shown in Table 1 . HeLa cells were most susceptible to wild -type H1 virus -induced cell killing, Saos -2 cells were intermediately sensitive, whereas U2OS cells were rather resistant. As expected from previous work, normal human fibroblasts were far more resistant to wild -type H1 virus -induced killing than were all tumor cells.
The difference in susceptibility of the tumor lines to H1 parvovirus -mediated cell killing could be due to major differences in the transduction efficiency of these cell lines by parvovirus H1. To exclude this possibility, all three tumor lines were infected with the recombinant GFP parvovirus vector, and the transduction efficiency was analyzed by FACS ( Table 2) . As NS1 -driven GFP expression was readily detected in a large proportion of each tumor cell line, it can be concluded that all these cell lines can take up the parvovirus and express functional NS1 able to transactivate the P38 promoter directing the GFP gene quite efficiently.
Increased cytotoxicity of Apoptin -transducing parvovirus
To establish the added effect of Apoptin transgene expression affected to parvovirus -mediated cell killing, the induction of apoptosis by the recombinant H1 vectors was determined in the three selected tumor cell lines. Cells were inoculated with recombinant hH1 /GFP or hH1 /Apoptin virus, fixed at various times after infection, processed for indirect immunofluorescence for NS1 and GFP or Apoptin, and stained with DAPI to compare the relative cytotoxicities of the viruses. Cell killing was expressed as the fraction of NS1 -plus transgene -positive nuclei staining aberrantly with DAPI versus the total number of NS1 -plus transgenepositive nuclei inspected. This procedure further excludes any effect that differences in transduction efficiency between tumor cells may have on their apparent sensitivity to the viral toxicity. Aberrant nuclear staining consisted of irregular and weak DAPI staining as well as chromosomal condensation and fragmentation of the DNA ( Fig 3A ) , features that are characteristic of apoptosis. 23 Apoptin accumulated in the nucleus, confirming the predominant nuclear localization of this protein in human tumor cells. 9 Cells positive for GFP or Apoptin were also positive for NS1, reflecting the transcriptional dependency of the transgenes on NS1 expression.
The apoptosis induction by a recombinant parvovirus expressing the GFP transgene ( Fig 3B ) closely reflects the observed variant susceptibilities of the tested tumor cells to wild -type H1 parvovirus (see Table 1 ). HeLa cells are readily killed, whereas Saos-2 cells and U2OS cells show a diminishing susceptibility to the parvovirus toxicity. In contrast, the recombinant Apoptin parvovirus has a wider killing range than that of the GFP -transducing virus. Indeed, in both Saos -2 and U2OS cell lines, the Apoptin virus caused significantly more cell killing than that induced by the control GFP parvovirus. However, cytotoxicity induced by hH1 /Apoptin virus was not enhanced further in the already highly H1 virus susceptible cell line HeLa.
To exclude that the enhanced cytocidal effect of the recombinant Apoptin parvovirus in the resistant cell line U2OS was due to increased NS1 expression, immunoblot analysis was performed with U2OS cell extracts at various OLIJSLAGERS, DEGE, DINSART, ET AL: PARVOVIRUS -MEDIATED APOPTIN TRANSDUCTION time points after infection with Apoptin or control parvovirus. As shown in Figure 3C , neither an increase in NS1 expression nor an alteration in its phosphorylation pattern was observed in hH1 /Apoptin compared with the GFP control.
In conclusion, these results strongly suggest that the inclusion of Apoptin in a parvovirus vector is sufficient to render a death -resistant tumor cell into a sensitive one without hindering the infectivity of the ''viral vector.''
DISCUSSION
In this report we sought to determine whether a parvoviral vector can be engineered that has a broader range of action against different tumor-derived cells, in particular against tumor cells known to be fairly resistant to wild -type H1 parvoviruses. To this end we created a novel recombinant parvovirus, in which an H1 -based vector was supplemented with a transgene encoding the apoptosis -inducing protein, Apoptin. Expression of Apoptin during parvovirus replication in the producer cell line did not inhibit the process of viral production, as the titers of the resulting recombinant virus, hH1 /Apoptin, were similar to those of H1 virus -derived vectors carrying nontoxic cytokines 16, 22 or a marker gene (hH1 /GFP, this paper ). This observation is not surprising given that the adenoviral vectors carrying the Apoptin -encoding VP3 gene can be successfully produced. 15 It was previously shown that in vitro -transformed and tumor-derived human cells were more susceptible to parvovirus ( H1 or MVMp )-induced killing than the corresponding normal cells. 1 -3,21 This phenomenon of tumor cell susceptibility of parvovirus has also been described for primary human cancer cells, illustrating that established cell lines are acceptable models to determine cell sensitivity to parvovirus -induced cell death. 24, 25 We selected three different cell lines with high, intermediate, and low sensitivity to parvovirus NS1 -induced cytotoxicity. This difference was not a direct result of differences in infectivity, as a GFP -expressing parvovirus was shown to transduce the resistant U2OS cell line even better than the sensitive HeLa cell line. Moreover, the expression of NS1 was also the same in these two cell lines. Judging from the GFP and Apoptin expression in FACS and immune fluorescence staining, respectively, the capacity of NS1 to activate the P38 promoter was also indistinguishable, indicating that differential transactivating properties of NS1 were not the cause of the resistance of U2OS cells to cytotoxicity.
It is interesting to note that wild -type p53 expression and a decrease in the susceptibility of tumor cells to parvovirusinduced killing may be correlated. Specifically, p53 antagonists, such as some polyoma and adenovirus -transforming proteins 26 -28 or a p53 dominant negative mutant, 29 sensitized cells to parvovirus replication and cytopathicity, whereas subclones of a human leukemic cell line selected for their resistance to H1 parvovirus infection expressed p53, even though p53 expression was undetectable in the parental cell line. 29 In keeping with these observations, our finding that the most H1 virus -resistant osteosarcoma line ( U2OS ) can be distinguished from the sensitive Saos-2 osteosarcoma line by its expression of functional wild -type p53, 10 is consistent with this correlation. The mechanism by which U2OS cells, and to a lesser extent, Saos-2 cells, resist H1 virus cytopathic effect, despite an apparently successful initiation of the viral life cycle, is presently unknown. However, resistance does not seem to involve inhibition of NS1 expression nor its ability to transactivate the P38 promoter, an activity that would inhibit the expression of the transgene in this type of recombinant parvovirus vector.
Our data show that insertion of the gene encoding Apoptin will enable a parvovirus to eradicate tumor cells that are relatively resistant to a control recombinant parvovirus, although the already high susceptibility of HeLa cells to the intrinsic lytic activity of H1 virus masked the added benefit conferred by Apoptin versus a control transgene. The percentage of recombinant virus -killed cells was also higher than the fraction of GFP -positive cells as determined by FACS analysis ( compare Fig 3B and Table 2 ), demonstrating that the number of successful virus -infected cells must be greater than suggested from the GFP transduction data only. From the killing rates presented in Figure 3B and the clonogenic assays in Table 1 , we assume that in approximately 80% of the tumor cells NS1 is expressed. In a large fraction of recombinant virus -infected Saos -2 and U2OS cells, low cytotoxic NS1 levels will enable transactivation of the P38 promoter and induce the expression of GFP or Apoptin, but will be insufficient to kill by itself most of the infected cells.
The kinetics of cell killing by Apoptin in the two resistant U2OS and Saos -2 cell lines seem to be faster than that in HeLa cells, and closely follow the kinetics of cellular localization of Apoptin; namely in HeLa cells, Apoptin migrated more slowly to the nucleus compared to Saos -2 cells (data not shown ). It has been shown that nuclear localization of Apoptin is required for its apoptosis induction. 9 Moreover, the fact that Apoptin -mediated apoptosis is p53 independent contrasts with the apparent correlation between loss of p53 function and gain of sensitivity to NS1 -induced cytotoxicity. Therefore, in addition to added potency toward insensitive tumor types, another benefit of including Apoptin in a parvovirus is that the two entities apparently exploit independent apoptosisinducing pathways. Such independence decreases the probability of emergence of resistant subclones 29 after treatment with an Apoptin recombinant parvovirus.
In order for the hH1 /Apoptin virus to be viable in gene therapy, it must be nontoxic to normal cells. In this regard, it was important to determine whether the tumor specificity was retained. Here, we showed that only a small fraction of normal nonestablished human fibroblasts infected by parvovirus became positive for transgene (GFP ) expression. 30 The low fraction of transduced normal fibroblasts appears to express the transgene to similar levels as transformed fibroblasts. 30 The main difference between normal and transformed H1 -infected fibroblasts thus lies in the number of cells participating in viral DNA replication and expression. 30 Expression of a cytocidal transgene under the control of NS1 should, therefore, not further affect the cytotoxicity of a recombinant parvovirus. Indeed, at an MOI of 3, only 2% of normal VH10 cells showed NS1 expression when infected with the Apoptin recombinant parvovirus (data not shown ), a value that is close to the percent killing of these nonestablished cells by wild -type virus ( Table 1 ) . Thus, insertion of the Apoptin gene into the parvoviral vector instead of GFP did not greatly increase its killing effect. Furthermore, a second constraint restricts killing of untransformed cells by the Apoptin parvovirus, namely the well -established insensitivity of such cells to Apoptin's apoptotic effect. 9 Therefore, we conclude that the expression of Apoptin in an NS1 -dependent manner does not compromise the benign nature of parvovirus in normal fibroblasts.
In vitro data suggest that a variety of tumors may be targets for recombinant parvoviruses. Cases of particular interest include human leukemic cells, which appear to be particularly susceptible to infection with parvovirus H1 4, 31, 32 but not sensitive to infection by some other viruses that are currently being evaluated as vectors for tumor therapy, such
Cancer Gene Therapy, Vol 8, No 12, 2001 OLIJSLAGERS, DEGE, DINSART, ET AL: PARVOVIRUS -MEDIATED APOPTIN TRANSDUCTION as adenoassociated viruses and adenoviruses. 33, 34 Furthermore, parvoviruses offer distinct advantages as vectors over several other viruses, such as their oncotropism 1 -3 and failure to elicit deleterious (e.g., inflammatory ) reactions. 35 In addition, NS1 -expressing parvoviral vectors achieve remarkably high levels of transgene expression even after infection at low multiplicities, 22 which may be ascribedat least in part -to their capacity for DNA amplification in target cells. 8 Taken together, these observations suggest that modified parvovirus vectors have potential in the field of cancer gene therapy and deserve to be further evaluated in animal tumor models. Such an in vivo assessment has recently been initiated using recombinant parvoviruses that harbor various cytokine genes, and the results suggest that supplying parvoviruses with immune -modulating transgenes enhances their oncosuppressive activity. 8, 16, 36 However, two disadvantages are not addressed by this approach, namely the fact that certain tumor types are resistant to parvovirusmediated cytotoxicity ab initio or through re -expression of p53. 29 Our present work shows that it is possible to overcome resistance of tumor cells to parvovirus infection by the addition of Apoptin without losing its nontoxicity toward untransformed cells. This feature and the fact that the Apoptin gene is only 363 bp long opens the road for research into a replicative Apoptin -expressing parvovirus with a broader killing range, a reduced probability of emergence of resistant subclones and an uncompromised tumor specificity.
